Nature Communications (Jun 2022)
Inhibition of type 1 immunity with tofacitinib is associated with marked improvement in longstanding sarcoidosis
- William Damsky,
- Alice Wang,
- Daniel J. Kim,
- Bryan D. Young,
- Katelyn Singh,
- Michael J. Murphy,
- Joseph Daccache,
- Abigale Clark,
- Ruveyda Ayasun,
- Changwan Ryu,
- Meaghan K. McGeary,
- Ian D. Odell,
- Ramesh Fazzone-Chettiar,
- Darko Pucar,
- Robert Homer,
- Mridu Gulati,
- Edward J. Miller,
- Marcus Bosenberg,
- Richard A. Flavell,
- Brett King
Affiliations
- William Damsky
- Department of Dermatology, Yale School of Medicine
- Alice Wang
- Department of Dermatology, Yale School of Medicine
- Daniel J. Kim
- Department of Dermatology, Yale School of Medicine
- Bryan D. Young
- Section of Cardiovascular Medicine, Yale School of Medicine
- Katelyn Singh
- Department of Dermatology, Yale School of Medicine
- Michael J. Murphy
- Department of Dermatology, Yale School of Medicine
- Joseph Daccache
- Department of Dermatology, Yale School of Medicine
- Abigale Clark
- Kansas City University of Medicine and Biosciences
- Ruveyda Ayasun
- Laura and Isaac Perlmutter Cancer Center, New York University Langone Medical Center
- Changwan Ryu
- Seciton of Pulmonary, Critical Care, and Sleep Medicine, Yale School of Medicine
- Meaghan K. McGeary
- Department of Pathology, Yale School of Medicine
- Ian D. Odell
- Department of Dermatology, Yale School of Medicine
- Ramesh Fazzone-Chettiar
- Section of Cardiovascular Medicine, Yale School of Medicine
- Darko Pucar
- Department of Radiology and Biomedical Imaging, Yale School of Medicine
- Robert Homer
- Department of Pathology, Yale School of Medicine
- Mridu Gulati
- Seciton of Pulmonary, Critical Care, and Sleep Medicine, Yale School of Medicine
- Edward J. Miller
- Section of Cardiovascular Medicine, Yale School of Medicine
- Marcus Bosenberg
- Department of Dermatology, Yale School of Medicine
- Richard A. Flavell
- Department of Immunobiology, Yale School of Medicine
- Brett King
- Department of Dermatology, Yale School of Medicine
- DOI
- https://doi.org/10.1038/s41467-022-30615-x
- Journal volume & issue
-
Vol. 13,
no. 1
pp. 1 – 17
Abstract
Sarcoidosis is a heterogenous disorder often treated with glucocorticoids. Here the authors show, in an open label, non-randomized, single arm clinical trial involving 10 patients, that treatment with tofacitinib, a Janus kinase inhibitor, is associated with improved clinical symptoms and reduced activity of Th1 cytokines such as IFN-γ and IL-12.
